KO-2806 is under clinical development by Kura Oncology and currently in Phase I for Metastatic Renal Cell Carcinoma. According to GlobalData, Phase I drugs for Metastatic Renal Cell Carcinoma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KO-2806’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

KO-2806 overview

KO-2806 is under development for the treatment of solid tumors, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma and clear cell renal cell carcinoma. It act by targeting farnesyl trans transferase enzyme. It is administered through oral route.

Kura Oncology overview

Kura Oncology is a biopharmaceutical company that discovers and develops therapeutics for the treatment of solid tumors and blood cancers. The company’s lead drug candidate Tipifarnib, an inhibitor of farnesyl transferase, an oral investigational drug candidate intended for the treatment of various types of cancer including HRAS mutant head and neck cancer, peripheral T-cell lymphomas, myelodysplastic syndromes and chronic myelomonocytic leukemia. Its other candidates include KO-947, an investigational drug candidate for mitogen-activated protein kinase pathway tumors and KO-539, a small molecule inhibitor to treat acute leukemia. Kura Oncology is headquartered in San Diego, California, the US.

For a complete picture of KO-2806’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.